drugset / Trial / NCT00307229
Adenovirus Encoding Rat HER-2 in Patients With Metastatic Breast Cancer (AdHER2.1)
Phase 1
Completed
8 enrolled
Ontario Clinical Oncology Group (OCOG)
Canadian Breast Cancer Research Alliance · collabOntario Cancer Research Network · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To determine the maximum tolerated dose and/or maximum attainable dose of a vaccine consisting of adenovector expressing rat Her-2/neu in patients with metastatic or locally recurrent breast cancer.
Timeline
- Start
- 2006-03
- Primary completion
- 2009-07
- Completion
- 2012-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | adenoviral vector encoding rat Her-2/neu | Vaccine | 1e+07 unknown | Other |
| Subject | adenoviral vector encoding rat Her-2/neu | Vaccine | 5e+07 unknown | Other |
| Subject | adenoviral vector encoding rat Her-2/neu | Vaccine | 1e+08 unknown | Other |